ArrayExpress Uploader036732ValidationMLL-rearrangementwild type3Discoveryt(8;21)wild type4Discoveryt(15;17)FLT3-ITD mutant6Validationremaining cytogeneticswild type7ValidationMLL-rearrangementN/K-RAS mutant8Discoveryunknown cytogeneticsN/K-RAS mutant; FLT3-ITD mutant9Validationremaining cytogeneticsFLT3-ITD mutant10Discoveryunknown cytogeneticswild type11Discoveryremaining cytogeneticsNPM1 mutant12DiscoveryMLL-rearrangementwild type13ValidationMLL-rearrangementPTPN11 mutant14Validationunknown cytogeneticsNPM1 mutant; FLT3 mutant15Validationunknown cytogeneticsCEBPA mutant16Validationt(8;21)C-KIT mutant17ValidationMLL-rearrangementN/K-RAS mutant18DiscoveryCN-AMLNPM1 mutant; FLT3-ITD mutant19Discoveryt(8;21)N/K-RAS mutant20Discoveryinv(16)C-KIT mutant21Discoveryinv(16)C-KIT mutant22Validationremaining cytogeneticsN/K-RAS mutant23DiscoveryMLL-rearrangementwild type24Discoveryt(8;21)wild type25DiscoveryCN-AMLN/K-RAS mutant; NPM1 mutant26Discoveryremaining cytogeneticsCEBPA mutant27DiscoveryMLL-rearrangementwild type28DiscoveryMLL-rearrangementN/K-RAS mutant29Validationremaining cytogeneticswild type31Validationt(8;21)C-KIT mutant32Discoveryt(7;12)wild type33Validationinv(16)wild type34Discoveryremaining cytogeneticswild type35Discoveryremaining cytogeneticsN/K-RAS mutant40Validationt(8;21)FLT3-ITD mutant44ValidationMLL-rearrangementwild type45Discoveryt(8;21)C-KIT mutant46Discoveryinv(16)C-KIT mutant47Validationinv(16)N/K-RAS mutant48ValidationMLL-rearrangementN/K-RAS mutant49DiscoveryMLL-rearrangementwild type50ValidationCN-AMLNPM1 mutant; FLT3-ITD mutant51Validationt(8;21)C-KIT mutant52Discoveryremaining cytogeneticswild type53Discoveryt(8;21)wild type54Validationremaining cytogeneticsCEBPA mutant55Discoveryremaining cytogeneticsFLT3-ITD mutant56Discoveryremaining cytogeneticsFLT3-ITD mutant57ValidationCN-AMLMLL-PTD mutant58DiscoveryMLL-rearrangementwild type59DiscoveryMLL-rearrangementFLT3-ITD mutant60DiscoveryMLL-rearrangementwild type61DiscoveryMLL-rearrangementwild type66Discoveryremaining cytogeneticsMLL-PTD mutant; N/K-RAS mutant122Discoveryremaining cytogeneticswild type123Validationremaining cytogeneticswild type124ValidationMLL-rearrangementwild type125Discoveryremaining cytogeneticswild type127ValidationCN-AMLFLT3-ITD mutant128Validationinv(16)C-KIT mutant129DiscoveryMLL-rearrangementwild type130DiscoveryCN-AMLN/K-RAS mutant; NPM1 mutant131DiscoveryCN-AMLN/K-RAS mutant; FLT3-ITD mutant132Discoveryt(8;21)N/K-RAS mutant133DiscoveryCN-AMLFLT3-ITD mutant134Discoveryremaining cytogeneticswild type135Discoveryt(8;21)wild type136Discoveryt(8;21)wild type137Discoveryinv(16)wild type138Validationt(8;21)wild type139Discoveryt(15;17)FLT3-ITD mutant140Discoveryt(15;17)wild type141DiscoveryMLL-rearrangementwild type142Discoveryremaining cytogeneticswild type143DiscoveryMLL-rearrangementwild type144DiscoveryCN-AMLCEBPA mutant145DiscoveryMLL-rearrangementN/K-RAS mutant146ValidationCN-AMLFLT3-ITD mutant147Discoveryt(8;21)wild type148Discoveryt(8;21)FLT3-ITD mutant149DiscoveryCN-AMLMLL-PTD mutant; FLT3-ITD mutant151Discoveryremaining cytogeneticswild type152Discoveryremaining cytogeneticswild type153DiscoveryCN-AMLwild type154DiscoveryCN-AMLFLT3-ITD mutant155Validationunknown cytogeneticsCEBPA mutant157Discoveryremaining cytogeneticswild type158Discoveryremaining cytogeneticswild type159Discoveryremaining cytogeneticsPTPN11 mutant160DiscoveryMLL-rearrangementwild type161Discoveryremaining cytogeneticsN/K-RAS mutant162DiscoveryMLL-rearrangementN/K-RAS mutant163Discoveryunknown cytogeneticswild type164Discoveryremaining cytogeneticsCEBPA mutant; FLT3-ITD mutant165Validationunknown cytogeneticsCEBPA mutant166DiscoveryMLL-rearrangementC-KIT mutant167Discoveryremaining cytogeneticswild type168Discoveryunknown cytogeneticsPTPN11 mutant169Discoveryinv(16)C-KIT mutant170Discoveryremaining cytogeneticswild typearrayexpress_sid4High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of...20522712E-GEOD-22056/profile/8773/arrayexpressuploader498bonebone marrowperipheralDec.12, 2014Falsetranscription-profiling-by-array-of-human-acute-2E-GEOD-22056_A-AFFY-44Transcription profiling by array of human acute myeloid leukemia patientsSep.15, 2014High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of VEGFC on long-term outcome and its associated gene expression profiles remain to be defined. We studied the effect of VEGFC on treatment outcome and investigated gene expression profiles associated with VEGFC using microarray data of 525 adult and 100 pediatric AML patients. High VEGFC expression appeared strongly associated with reduced complete remission rate, reduced overall and event-free survival (OS and EFS) in adult AML. Multivariable analysis established high VEGFC as prognostic indicator independent of cytogenetic risk, FLT3-ITD, NPM1, CEBPA, age and WBC. Also in pediatric AML high VEGFC was related to reduced OS. A unique series of differentially expressed genes was identified that distinguished AML with high VEGFC from AML with low VEGFC, i.e., 331 upregulated genes (representative of proliferation, VEGF-receptor activity, signal transduction) and 44 downregulated genes (e.g. related to apoptosis) consistent with a role in enhanced chemoresistance. In conclusion, high VEGFC predicts adverse long-term prognosis and provides prognostic information in addition to well-known prognostic factors. 98 bone marrow and peripheral blood samples were collected at diagnosis and frozen. They were later thawed and hybridized to Affymetrix U133 Plus 2.0 arrays.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22056humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22056/samples/